WO2021197880A1 - Process for preparation of optically enriched isoxazolines - Google Patents

Process for preparation of optically enriched isoxazolines Download PDF

Info

Publication number
WO2021197880A1
WO2021197880A1 PCT/EP2021/057228 EP2021057228W WO2021197880A1 WO 2021197880 A1 WO2021197880 A1 WO 2021197880A1 EP 2021057228 W EP2021057228 W EP 2021057228W WO 2021197880 A1 WO2021197880 A1 WO 2021197880A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
crc
ring
partially
alkenyl
Prior art date
Application number
PCT/EP2021/057228
Other languages
French (fr)
Inventor
Karsten KÖRBER
Rosario Aleyda GARZA SANCHEZ
Kailaskumar Borate
Nikolas HUWYLER
Birte SCHRÖDER
Michael Rack
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of WO2021197880A1 publication Critical patent/WO2021197880A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the invention relates to a process for the preparation of optically enriched isoxazoline com pounds of formula I wherein
  • R 1 is halomethyl; each R 2 is independently H, halogen, CN, l ⁇ , NO2, SCN, SF5, CrC 6 -alkyl, Cs-Cs-cycloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, which groups are unsubstituted, partially or fully halogenated and/or substituted with one or more same or different R 8 ;
  • OR 9 or S(0) n R 9 , n is 0, 1, or 2;
  • W is O or S
  • R 5 is independently selected from the meanings mentioned for R 2 ;
  • R 10a , R i o b are independently from one another H, CrC 6 -alkyl, CrC 6 -haloalkyl, C 3 -C 8 -cycloal- kyl, Cs-Cs-halocycloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C2-C6-haloalky- nyl;
  • R 11 is halogen, CN, N 3 , NO 2 , SCN, SF 5 , Ci-Cio-alkyl, C 3 -C8-cycloalkyl, C 2 -Cio-alkenyl, C 2 -C 10 - alkynyl, or
  • R a is CN, Ci-C3-alkyl, CrC3-alkoxy, CrC3-alkylthio, phenyl, benzyl, and phenoxy; R b is halogen; p is 1, 2, 3, or 4; and q is 0, 1 , 2 or 3, wherein the sum of p and q is up to 4; and a base.
  • the isoxazoline active compounds I and their pesticidal activity are generally known from W02007/105814.
  • W02009/063910 describes asymmetric syntheses of some isooxazoline compounds of formula I by using cinchona alkaloid-based phase-transfer catalysts.
  • the processes require relatively high catalyst loadings and yield enantiomeric excesses of formula I compounds which still leave room for improvement.
  • Objective task for the invention therefore is providing an economical, industrially applicable manufacturing process for optically enriched compounds of formula I. This task is achieved by the process defined in the outset.
  • the presence of a catalyst III as defined herein in the reaction of compound II ensures a quick and effective transformation at moderate temperatures.
  • the formula III catalyst is novel.
  • this catalyst is used in asymmetric oxa-Michael addition of hydroxyl amine with an enone to form an enantioselective C-0 bond.
  • the process yields formula I compounds in good yield with at least 55% ee by using low catalyst loadings.
  • reaction of an enone of formula II, wherein the variables have the meanings given in the outset, with hydroxyl amine or its salt is usually carried out at temperatures of from -30°C to 35°C, preferably from -10°C to 0°C, in an inert solvent, in the presence of a catalyst of formula III.
  • Suitable solvents are preferably water immiscible solvents, such as aliphatic hydrocarbons such as pentane, hexane, cyclohexane, and petrol ether, aromatic hydrocarbons such as toluene, o-, m-, and p-xylene, halogenated hydrocarbons such as methylene chloride, dichloroethane, and chloroform, ethers such as diethylether, diisopropylether, tert.-butyl- methylether (MTBE), anisole, and ketones such as methyl ethyl ketone, diethyl ketone, and tert.-butyl methyl ketone, alcohols such as, n-propanol, n-butanol, preferably halogenated hydrocarbons such as methylene chloride, dichloroethane, and chloroform. It is also possible to use mixtures of the solvents mentioned.
  • Suitable bases are in general, inorganic compounds, such as alkali metal and alkaline earth metal hydroxides, such as LiOH, NaOH, KOH and Ca(OH)2, alkali metal and alkaline earth metal oxides, such as U2O, Na 2 0, CaO, and MgO, and alkaline earth metal carbonates, such as U2CO3, Na 2 CC>3, K2CO3 and CaCC>3, and also alkali metal bicarbonates, such as NaHCC>3, moreover organic bases, e.g.
  • alkali metal and alkaline earth metal hydroxides such as LiOH, NaOH, KOH and Ca(OH)2
  • alkali metal and alkaline earth metal oxides such as U2O, Na 2 0, CaO, and MgO
  • alkaline earth metal carbonates such as U2CO3, Na 2 CC>3, K2CO3 and CaCC>3, and also alkali metal bicarbonates, such as NaHCC>3, moreover organic bases, e.g.
  • tertiary amines such as trimethylamine, triethylamine (NEts), diisopropylethylamine and N-methylpiperidine, pyridine, substituted pyridines, such as collidine, lutidine and 4-dimethylaminopyridine, and also bicyclic amines, such as DBU (1,8-Diaza- bicyclo(5.4.0)undec-7-ene) and DBN (1,5-Diazabicyclo[4.3.0]non-5-ene).
  • alkali metal and alkaline earth metal hydroxides such as LiOH, NaOH, KOH, and Ca(OH)2, such as NaOH, and KOH.
  • the bases are generally employed in catalytic amounts; however, they can also be used in equimolar amounts or in excess. Under certain conditions an excess up to 10 mol equivalents of base to compound II may be advantageous.
  • hydroxylamine is preferably used in the form of an aqueous solution, alternatively as acid addition salt, such as halogenide or sulfate, preferably halogenide, particularly as HCI addition salt.
  • Hydroxylamine is generally employed in equimolar amounts; however, it can also be used in excess. Under certain conditions an excess up to 10 mol equivalents of hydroxylamine to compound II may be advantageous.
  • the catalyst III is used in 0.01 to 0.5, preferably 0.01 to 0.2, particularly about 0.02 to 0.1 mol equivalents of compound II.
  • the starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of hydroxyl amine, based on II.
  • Compounds of formula III can preferably be prepared by alkylation of (R)-(6-methyl-4-quinolyl)- (5-vinylquinuclidin-2-yl)methanol (formula IV) with a compound of formula V wherein X is a leaving group, such as hydroxy or halogen, preferably Br or Cl; and R a , R b , p, and q have the meaning as given for formula III.
  • This transformation is usually carried out at temperatures of from 20°C to 110 °C, preferably from 25°C to 80°C, in an inert solvent [cf. WO 2011/104089]
  • Suitable solvents are aliphatic hydrocarbons such as pentane, hexane, cyclohexane, and petrol ether, aromatic hydrocarbons such as toluene, o-, m-, and p-xylene, halogenated hydrocarbons such as methylene chloride, chloroform, and chlorobenzene, ethers such as diethylether, diisopropylether, MTBE, dioxane, anisole, and tetrahydrofurane, nitrils such as acetonitrile, and propionitrile, moreover dimethyl sulphoxide, dimethyl formamide, and dimethylacetamide (DMA), preferably toluene, or acetonitrile. It is also possible to use mixtures of the solvents mentioned.
  • aromatic hydrocarbons such as toluene, o-, m-, and p-xylene
  • halogenated hydrocarbons such as methylene chlor
  • Formula IV and V compounds are known in the art and are commercially available.
  • reaction mixtures are worked up in a customary manner, for example by mixing with water, separating the phases and, if appropriate, chromatographic purification of the crude products.
  • Some of the intermediates and end products are obtained in the form of colourless or slightly brownish viscous oils which are purified or freed from volatile components under reduced pressure and at moderately elevated temperature. If the intermediates and end products are obtained as solids, purification can also be carried out by recrystallization or digestion.
  • the organic moieties mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members.
  • the prefix C n - C m indicates in each case the possible number of carbon atoms in the group.
  • halogen denotes in each case fluorine, bromine, chlorine, or iodine, in particular fluorine, chlorine, or bromine.
  • alkyl as used herein and in the alkyl moieties of alkylamino, alkylcarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl and alkoxyalkyl denotes in each case a straight-chain or branched al kyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, prefer ably 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms.
  • alkyl group examples include methyl (“Me”), ethyl (“Et”), n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl (“ l Bu”), n-pentyl, 1 -methyl butyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4- methylpentyl, 1 ,1-dimethylbutyl, 1 ,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,
  • haloalkyl as used herein and in the haloalkyl moieties of haloalkylcarbonyl, haloalk- oxycarbonyl, haloalkylthio, haloalkylsulfonyl, haloalkylsulfinyl, haloalkoxy and haloalkoxyalkyl, denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 car bon atoms, frequently from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms.
  • Preferred haloalkyl moieties are selected from CrC4-haloalkyl, more preferably from CrC3-haloalkyl or CrC2-haloalkyl, in particular from Ci-C2-fluoroalkyl such as fluoromethyl, difluoromethyl, triflu- oromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2, 2-trif I u oroethy I , pentafluoroethyl, and the like.
  • alkoxy denotes in each case a straight-chain or branched alkyl group which is bonded via an oxygen atom and has usually from 1 to 10 carbon atoms, fre quently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms.
  • alkoxy group examples are methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyloxy, 2-butyloxy, iso-butyloxy, tert.-butyloxy, and the like.
  • alkoxyalkyl refers to alkyl usually comprising 1 to 10, frequently 1 to 4, preferably 1 to 2 carbon atoms, wherein 1 carbon atom carries an alkoxy radical usually comprising 1 to 4, preferably 1 or 2 carbon atoms as defined above. Examples are CH2OCH3, CH2-OC2H5, 2-(methoxy)ethyl, and 2-(ethoxy)ethyl.
  • haloalkoxy denotes in each case a straight-chain or branched alk oxy group having from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular fluorine atoms.
  • haloalkoxy moieties include C1-C4- haloalkoxy, in particular CrC2-fluoroalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoro- methoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2- fluoroethoxy, 2-chloro-2,2-difluoro-ethoxy, 2,2dichloro-2-fluorethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and the like.
  • alkylthio (alkylsulfanyl: S-alkyl)
  • alkoxycarbonyl refers to an alkylcarbonyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
  • alkenyl denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl (2-methylprop-2-en-1-yl), 2-buten-1-yl, 3- buten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl, 2-ethylprop-2-en- 1-yl and the like.
  • haloalkenyl refers to an alkenyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.
  • alkynyl denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. ethynyl, propargyl (2-propyn-1-yl), 1-propyn-1-yl, 1-methylprop-2-yn-1-yl), 2-butyn-1-yl, 3-butyn-1-yl, 1- pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl, 1-methylbut-2-yn-1-yl, 1-ethylprop-2-yn-1-yl and the like.
  • cycloalkyl as used herein and in the cycloalkyl moieties of cycloalkoxy and cyclo- alkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl , cyclooctyl, cyclononyl, and cyclodecyl, or cyclopropyl (C-C 3 H5), cyclobutyl (C-C4H7), cyclopentyl (C-C5H 9 ), and cyclohexyl (c-CeHn).
  • halocycloalkyl as used herein and in the halocycloalkyl moieties of halocycloalkoxy and halocycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 C atoms or 3 to 6 C atoms, wherein at least one, e.g. 1, 2, 3, 4 or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine.
  • Examples are 1- and 2-flu- orocyclopropyl, 1,2-, 2,2- and 2,3-difluorocyclopropyl, 1,2,2-trifluorocyclopropyl, 2, 2,3,3- tetrafluorocyclpropyl, 1- and 2-chlorocyclopropyl, 1,2-, 2,2- and 2,3-dichlorocyclopropyl, 1,2,2- trichlorocyclopropyl, 2,2,3,3-tetrachlorocyclpropyl, 1-,2- and 3-fluorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-difluorocyclopentyl, 1-,2- and 3-chlorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5- dichlorocyclopentyl, and the like.
  • cycloalkenyl as used herein and in the cycloalkenyl moieties of cycloalkenyloxy and cycloalkenylthio denotes in each case a monocyclic singly unsaturated non-aromatic radical ha ving usually from 3 to 10, e.g. 3 or 4 or from 5 to 10 carbon atoms, preferably from 3- to 8 carbon atoms.
  • exemplary cycloalkenyl groups include cyclopropenyl, cycloheptenyl or cyclo- octenyl.
  • carrier or “carbocyclyl” includes in general a 3- to 12-membered, preferably a 3- to 8-membered or a 5- to 8-membered, more preferably a 5- or 6-membered mono-cyclic, non-aromatic ring comprising 3 to 12, preferably 3 to 8 or 5 to 8, more preferably 5 or 6 carbon atoms.
  • the term “carbocycle” covers cycloalkyl and cycloalkenyl groups as defined above.
  • heterocycle or “heterocyclyl” includes in general 3- to 12-membered, preferably 5- or 6-membered, in particular 6-membered monocyclic heterocyclic non-aromatic radicals.
  • the heterocyclic non-aromatic radicals usually comprise 1, 2 or 3 heteroatoms selected from N, O and S as ring members, wherein S-atoms as ring members may be present as S, SO or SO2.
  • Examples of 5- or 6-membered heterocyclic radicals comprise saturated or unsaturated, non aromatic heterocyclic rings, such as 2- and 3-azetidinyl, 2- and 3-oxetanyl, 2- and 3-thietanyl, 2- and 3-thietanyl-S-oxid (S-oxothietanyl), 2- and 3-thietanyl-S-dioxid (S-dioxothietanyl), 2- and 3- pyrrolidinyl, 2- and 3-tetrahydrofuranyl, 1,3-dioxolan-2-yl, thiolan-2-yl, S-oxothiolan-2-yl, S-di- oxothiolan-2-yl, 4- and 5-oxazolidinyl, 1,3-dioxan-2-yl, 1- and 3-thiopyran-2-yl, S-oxothiopyranyl, and S-dioxothiopyranyl.
  • heteroaryl includes monocyclic 5- or 6-membered heteroaromatic radicals comprising as ring members 1 , 2, or 3 heteroatoms selected from N, O and S.
  • 5- or 6-mem- bered heteroaromatic radicals include pyridyl, i.e. 2-, 3-, and 4-pyridyl, pyrimidinyl, i.e. 2-, 4- and 5-pyrimidinyl, pyrazinyl, pyridazinyl, i.e. 3- and 4-pyridazinyl, thienyl, i.e. 2- and 3-thienyl, furyl, i.e. 2- and 3-furyl, pyrrolyl, i.e.
  • variables of the compounds of the formula I have the following meanings, these meanings, both on their own and in combination with one another, being particular embodiments of the compounds of formula I.
  • R 1 is preferably fluoromethyl, in particular CF3.
  • the phenyl ring in formula I and its sub formulae, bearing the R 2 n substitution is preferably a group P
  • R 2a is preferably selected from
  • R 2b and R 2c are independently preferably selected from H, F, Cl, Br, CF 3 , and OCF 3 .
  • each one of the following combinations of R 2a , R 2b , and R 2c wherein each line of Table A denotes a substitution pattern of the phenyl ring P bearing the R 2a , R 2b , and R 2c moieties.
  • Table A denotes a substitution pattern of the phenyl ring P bearing the R 2a , R 2b , and R 2c moieties.
  • Groups A-8, A-9, and A-11 are more preferred patterns in formula I and its sub formulae compounds. A-11 is particularly preferred.
  • R 3 is preferably H, halogen, or CH 3 .
  • G 1 and G 2 represent each CR 3 , wherein R 3 is H, halogen, or C1-C4- alkyl, particularly G 1 is CH and G 2 is C-CI, or C-CH 3 .
  • G 1 and G 2 represent each CR 3 , wherein the two R 3 form a five- or sixmembered saturated carbocyclic ring, or a dihydrofurane.
  • the catalyst III is used preferably in an amount of 0.1-50 mol%, more preferred in 0.5-25 mol%, particularly in 1-10 mol% relative to formula II compounds.
  • the nature of the counteranion X- in formula III catalyst is of minor importance. For practical reasons it is usually selected from halogen (preferably Cl, Br), BF4, PF 6 , CrCio-alkylsulfonate, benzenesulfonate, or methylbenzenesulfonate.
  • Preferred III is used as bromide and chloride, mesylate, and tosylate. Particularly preferred are bromide and chloride.
  • R a is preferably CN, Ci-C3-alkyl, or Ci-C3-alkoxy, particularly CH3, or OCH3.
  • R b is preferably Cl.
  • Index p is preferably 1 or 2
  • q is preferably 0 or 1.
  • Substituents R a and R b are preferably positioned in 2 and 6 position.
  • catalysts of formula III wherein the substitution of the pyridine group have the meanings as shown in Table II 1.1 , wherein each compound corresponds to one line.
  • Table 111.1 is particularly preferred.
  • bromides and chlorides of ill-1, 111-12, 111-21 , ill-26, and ill-27 are preferred embodiments.
  • R 5 is H or CH3
  • R 6 is H, CrC 6 -alkyl, C2-C6-alkenyl, which groups are unsubstituted or substituted with one or more same or different R 8 , wherein R 8 is as defined and preferred above.
  • R 5 is H or CH3
  • R 6 is H, CrC 6 -alkyl, CrC4-alkoxy, or C2-C6-alkenyl, which groups are unsubstituted or substituted with one or more same or different R 8 , wherein R 8 is as defined and preferred above.
  • the process is particularly suitable for synthesis of following active compounds of formula I, which correspond to formulae I. A, and I.B, resp., wherein the variables are as defined and preferred above: wherein Q is CH or O; and the other variables are as defined and preferred for formula I, and wherein R 3 is preferably H, CH 3 , or Cl, more preferably CH 3 or Cl.
  • R 5 is preferably H or CH 3
  • R 6 is preferably H, CrC 6 -alkyl, Cr C2-alkoxy-CrC2-alkyl, or C2-C6-alkenyl.
  • R 5 is preferably H or CH 3
  • R 6 is preferably H, CrC 6 -alkyl, or CrC4-alkoxy.
  • the process yields in formula I compounds which obtained from the raw reaction mixture have an ee of at least 60%, more preferably 70%, even more preferably 80%, particularly at least 90% ee. Further enrichment of the S-enantiomer can be achieved by following recrystallisation.
  • HPLC-MS high performance liquid chromatography-coupled mass spectrometry
  • HPLC Method A Agilent Series 1100, Column: Chiralpak AD-RH, 150mm * 4.6 mm ID * 5pm; Mobile Phase: A: water + 0,1vol% H3P04; B: acetonitrile + 0,1vol% H3P04; Temperature:
  • Example 1 (R)-[(2S,4S,5R)-1-[(2-chloro-6-methoxy-4-pyridyl)methyl]-5-vinyl-quinuclidin-1-ium- 2-yl]-(6-methoxy-4-quinolyl)methanol chloride [111.2-2] To a solution of quinine [(R)-(6-methoxy-4-quinolyl)-[(2S,4S,5R)-5-vinylquinuclidin-2-yl]metha- nol, 844 mg, 2.60 mmol] in acetonitrile (10 ml_) was added 4-chloromethyl-2-chloro-6-methoxy pyridine (500 mg, 2.60 mmol) and the mixture was stirred at reflux overnight. After completion of the reaction, the mixture was diluted with MTBE (100 ml_) and the resulting precipitate was collected via filtration. After drying in vacuum, the title compound was obtained (780 mg, 52%) as color
  • Step 3 Preparation of (R)-[(2S,4S,5R)-1-[(2,6-dimethyl-4-pyridyl)methyl]-5-vinyl-quinuclidin-1- ium-2-yl]-(6-methoxy-4-quinolyl)methanol bromide [111.2-4]
  • aqueous NaOH (1.69 g of a 20% solution in water, 8.47 mmol, 4 equiv.) and hydroxylamine (0.42 g of a 50% solution in water, 6.35 mmol, 3 equiv.) was added slowly.
  • aqueous hydrochloric acid (10 mL of a 1 M solution) was added and allowed to reach room temperature. All volatile solvents were removed in vacuum, then water (20 mL) was added and sonicated.
  • Step 3 Preparation of tert-butyl N-[(7-acetylindan-4-yl)methyl]carbamate
  • Step 4 Preparation of tert-butyl N-[[7-[(E/Z)-3-(3,5-dichloro-4-fluoro-phenyl)-4,4,4-trifluoro-but- 2-enoyl]indan-4-yl]methyl]carbamate
  • Step 5 Preparation of tert-butyl N-[[7-[(5S)-5-(3,5-dichloro-4-fluoro-phenyl)-5-(trifluoromethyl)- 4H-isoxazol-3-yl]indan-4-yl]methyl]carbamate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I), formula (I), wherein the variables are as defined in the specification, and the shown enantiomer has at least 55% ee; by oxo-Michael addition of hydroxyl amine or its salt to an enone of formula (II), formula (II), wherein the variables have the meanings given for formula (I), in the presence of a catalyst of formula (III), formula (III), and a base, the invention furthermore relates to novel compounds of formula (III).

Description

Process for preparation of optically enriched isoxazolines
Description
The invention relates to a process for the preparation of optically enriched isoxazoline com pounds of formula I
Figure imgf000002_0001
wherein
R1 is halomethyl; each R2 is independently H, halogen, CN, l\ , NO2, SCN, SF5, CrC6-alkyl, Cs-Cs-cycloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, which groups are unsubstituted, partially or fully halogenated and/or substituted with one or more same or different R8;
OR9, or S(0)nR9, n is 0, 1, or 2;
G1, G2 are each CR3; each R3 is independently selected from the meanings mentioned for R2or is C(=0)R8, or two R3 bonded to adjacent carbon atoms may form a five- or sixmembered saturated, par tially or fully unsaturated carbocyclic ring, or a dihydrofurane;
W is O or S;
R5 is independently selected from the meanings mentioned for R2;
R6 is H, Ci-Cio-alkyl, Cs-Cs-cycloalkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, which groups are un substituted, partially or fully halogenated and/or substituted with one or more same or dif ferent R8; or CrC4-alkoxy, S(0)nR9, or C(=0)R8; or a 3- to 8-membered saturated, partially or fully unsaturated heterocyclic ring, which ring may contain 1 , 2, 3, or 4 heteroatoms O, S, N, C=0 and/or C=S as ring members, which heterocyclic ring is unsubstituted or partially or fully substituted with same or different hal ogen, CN, CrC6-alkyl, CrC6-haloalkyl, CrC6-alkoxy, CrC6-haloalkoxy, CrC6-alkylthio, CrC6-haloalkylthio, Cs-Cs-cycloalkyl, C3-Cs-halocycloalkyl, C2-C6-alkenyl, C2-C6-haloal- kenyl, C2-C6-alkynyl, C2-C6-haloalkynyl, which groups are unsubstituted, or partially or fully substituted with same or different R8, or phenyl which may be partially or fully substituted with R11; each R8 is independently CN, N3, NO2, SCN, SF5, Cs-Cs-cycloalkyl, C3-Cs-halocycloalkyl; Si(R12)3, OR9, OSO2R9, S(0)nR9, N(R10a)R10b, C(=O)N(R10a)R10b, C(=S)N(R10a)R10b, C(=0)0R9, CH=NOR9, phenyl, or a 3-, 4-, 5-, 6- or 7-membered saturated, partially or fully unsaturated heterocyclic ring comprising 1, 2 or 3 heteroatoms N, O, and/or S as ring members, or two R8 present on the same carbon atom of an alkyl, alkenyl, alkynyl or cycloalkyl group together form a group = =NOR9; or =NN(R10a)R1
Figure imgf000002_0002
two radicals R8, together with the carbon atoms of the alkyl, alkenyl, alkynyl or cycloalkyl group which they are bonded to, form a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or partially unsaturated carbocyclic or heterocyclic ring, which heterocyclic ring comprises 1, 2, 3 or 4 heteroatoms N, O, and/or S as ring members; and R8 as a substituent on a cycloalkyl ring may additionally be CrC6-alkyl, CrC6-haloalkyl, C2-C6- alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, and C2-C6-haloalkynyl; and R8 in the groups C(=0)R8 and =C(R8)2 may additionally be H, halogen, CrC6-alkyl, CrC6-halo- alkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, or C2-C6-haloalkynyl; each R9 is independently H, CrC6-alkyl, or CrC6-haloalkyl;
R10a, Riob are independently from one another H, CrC6-alkyl, CrC6-haloalkyl, C3-C8-cycloal- kyl, Cs-Cs-halocycloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C2-C6-haloalky- nyl;
Ci-Ce-alkyl-C(=0)OR15, Ci-C6-alkyl-C(=0)N(R14a)R14b, Ci-C6-alkyl-C(=S)N(R14a)R14b, Ci-C6-alkyl-C(=NR14)N(R14a)R14b, CrCe-alkoxy, CrCe-haloalkoxy, Ci-C6-alkylthio, Ci-C6- haloalkylthio, S(0)nR15, S(0)nN(R14a)R14b, C(=0)R13, C(=0)OR15, C(=0)N(R14a)R14b, C(=S)R13, C(=S)SR15, C(=S)N(R14a)R14b, C(=NR14)R13; phenyl; and a 3-, 4-, 5-, 6- or 7-membered saturated, partially or fully unsaturated heterocyclic ring comprising 1, 2, 3 or 4 heteroatoms N, O, and/or S as ring members, preferably hetaryl; or R10a and R10b together with the nitrogen atom they are bonded to form a 3- to 8-membered saturated, partially or fully unsaturated heterocyclic ring, which ring may additionally contain one or two heteroatoms N, O, and/or S as ring members; or R10a and R10b together form a group =C(R13)2, =S(0)m(R15)2, =S(0)mR15N(R14a)R14b, =NR14, or =NOR15;
R11 is halogen, CN, N3, NO2, SCN, SF5, Ci-Cio-alkyl, C3-C8-cycloalkyl, C2-Cio-alkenyl, C2-C10- alkynyl, or
OR9, NR10aR10b, S(0)nR9, Si(R12)3; phenyl; and a 3- to 7-membered saturated, partially or fully unsaturated aromatic heterocyclic ring comprising 1 , 2, 3, or 4 heteroatoms N, O, and/or S as ring members; or two R11 present on the same ring carbon atom of an unsaturated or partially unsaturated heterocyclic ring may together form a group =0, =C(R13)2, =S, =S(0)m(R15)2, =S(0)mR15N(R14a)R14b, =NR14, =NOR15, or =NN(R14a)R14b; or two R11 bound on adjacent ring atoms form together with the ring atoms to which they are bound a saturated 3- to 9-membered ring, which ring may contain 1 or 2 heteroatoms O,
S, N, and/or NR14, and/or 1 or 2 groups C=0, C=S, C=NR14 as ring members; each R12 is independently CrC4-alkyl and phenyl; each R13 is independently CN, NO2, OH, SH, SCN, SF5, CrC6-alkoxy, CrC6-haloalkoxy, SOn- CrCe-alkyl, SOn-Ci-C6-haloalkyl, Si(R12)3, C(=0)N(R14a)R14b,
OrCs-cycloalkyl; and a 3- to 7-membered saturated, partially or fully unsaturated heterocyclic ring containing 1, 2, or 3 heteroatoms N, O, and/or S, as ring members; or two R13 present on the same carbon atom of an alkyl, alkenyl, alkynyl or cycloalkyl group may together be =0, =CH(Ci-C4-alkyl), =C(Ci-C4-alkyl)Ci-C4-alkyl, =N(Ci-C6-alkyl) or =NO(Ci- Ce-alkyl); and
R13 as a substituent of a cycloalkyl ring may additionally be Ci-Ce-alkyl, C2-C6-alkenyl or C2-C6- alkynyl, which groups are unsubstituted, partially or fully halogenated, or substituted with 1 or 2 CN, C3-C4-cycloalkyl, CrC4-alkoxy, CrC4-haloalkoxy, and oxo; and R13 in groups =C(R13)2, N=C(R13)2, C(=0)R13, C(=S)R13, and C(=NR14)R13 may additionally be H, halogen, Ci-Ce-alkyl, C2-C6-alkenyl, or C2-C6-alkynyl, and oxo; each R14 is independently H, CN, CrC6-alkoxy, CrC6-haloalkoxy, SOn-Ci-Ce-alkyl, SOn-Cr Ce-haloalkyl, Si(R12)3; Ci-Ce-alkyl, C2-Ce-alkenyl, C2-Ce-alkynyl; and oxo; C3-C8-cycloalkyl; phenyl, benzyl, pyridyl, phenoxy; and a 3-, 4-, 5- or 6-membered saturated, partially or fully unsaturated heterocyclic ring comprising 1 , 2 or 3 heteroatoms N, O, and/or S as ring members;
R14a and R14b independently of each other, have one of the meanings given for R14; or R14a and R14b, together with the nitrogen atom to which they are bound, form a 3- to 7- membered saturated, partially, or fully unsaturated heterocyclic ring, wherein the ring may additionally contain 1 or 2 heteroatoms N, O, and/or S as ring members; or R14a and R14 or R14b and R14, together with the nitrogen atoms to which they are bound in the group C(=NR14)N(R14a)R14b, form a 3- to 7-membered partially, or fully unsaturated heterocyclic ring, wherein the ring may additionally contain 1 or 2 heteroatoms N, O, and/or S as ring members; each R15 is independently H, CN, Si(R12)3, CrC6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl; C3-C8- cycloalkyl; phenyl, benzyl, pyridyl, and phenoxy; each R16 is independently halogen, NO2, CN, OH, SH, CrC6-alkoxy, CrC6-haloalkoxy, SOn- CrC6-alkyl, SOn-CrC6-haloalkyl, CrC4-alkylcarbonyl, CrC4-haloalkylcarbonyl, C1-C4- alkoxycarbonyl, Ci-C4-haloalkoxycarbonyl, aminocarbonyl, Ci-C4-alkylaminocarbonyl, di- (Ci-C4-alkyl)-aminocarbonyl, Si(R12)3; CrCe-alkyl, C2-Ce-alkenyl, C2-Ce-alkynyl; C3-C8- cycloalkyl; or two R16 present together on the same atom of an unsaturated or partially unsaturated ring may be =0, =S, =N(Ci-Ce-alkyl), =NO-Ci-C6-alkyl, =CH(Ci-C4-alkyl), or =C(Ci-C4-alkyl)2; or two R16 on two adjacent carbon atoms form together with the carbon atoms they are bonded to a 4- to 8-membered saturated, partially or fully unsaturated ring, wherein the ring may contain 1 or 2 heteroatoms N, O, and/or S as ring members; each n is independently 0, 1, or 2; and each m is independently 0, or 1 ; wherein the shown enantiomer has at least 55% ee; by oxo-Michael addition of hydroxyl amine or its salt to an enone of formula II,
Figure imgf000004_0001
wherein the variables have the meanings given for formula I, in the presence of a catalyst of formula III
Figure imgf000004_0002
wherein X is a counteranion, and
Ra is CN, Ci-C3-alkyl, CrC3-alkoxy, CrC3-alkylthio, phenyl, benzyl, and phenoxy; Rb is halogen; p is 1, 2, 3, or 4; and q is 0, 1 , 2 or 3, wherein the sum of p and q is up to 4; and a base. The isoxazoline active compounds I and their pesticidal activity are generally known from W02007/105814.
W02009/063910 describes asymmetric syntheses of some isooxazoline compounds of formula I by using cinchona alkaloid-based phase-transfer catalysts. The processes require relatively high catalyst loadings and yield enantiomeric excesses of formula I compounds which still leave room for improvement.
Objective task for the invention therefore is providing an economical, industrially applicable manufacturing process for optically enriched compounds of formula I. This task is achieved by the process defined in the outset. The presence of a catalyst III as defined herein in the reaction of compound II ensures a quick and effective transformation at moderate temperatures.
The formula III catalyst is novel.
In the invention this catalyst is used in asymmetric oxa-Michael addition of hydroxyl amine with an enone to form an enantioselective C-0 bond. The process yields formula I compounds in good yield with at least 55% ee by using low catalyst loadings.
The reaction of an enone of formula II, wherein the variables have the meanings given in the outset, with hydroxyl amine or its salt is usually carried out at temperatures of from -30°C to 35°C, preferably from -10°C to 0°C, in an inert solvent, in the presence of a catalyst of formula III.
Suitable solvents are preferably water immiscible solvents, such as aliphatic hydrocarbons such as pentane, hexane, cyclohexane, and petrol ether, aromatic hydrocarbons such as toluene, o-, m-, and p-xylene, halogenated hydrocarbons such as methylene chloride, dichloroethane, and chloroform, ethers such as diethylether, diisopropylether, tert.-butyl- methylether (MTBE), anisole, and ketones such as methyl ethyl ketone, diethyl ketone, and tert.-butyl methyl ketone, alcohols such as, n-propanol, n-butanol, preferably halogenated hydrocarbons such as methylene chloride, dichloroethane, and chloroform. It is also possible to use mixtures of the solvents mentioned.
Suitable bases are in general, inorganic compounds, such as alkali metal and alkaline earth metal hydroxides, such as LiOH, NaOH, KOH and Ca(OH)2, alkali metal and alkaline earth metal oxides, such as U2O, Na20, CaO, and MgO, and alkaline earth metal carbonates, such as U2CO3, Na2CC>3, K2CO3 and CaCC>3, and also alkali metal bicarbonates, such as NaHCC>3, moreover organic bases, e.g. tertiary amines, such as trimethylamine, triethylamine (NEts), diisopropylethylamine and N-methylpiperidine, pyridine, substituted pyridines, such as collidine, lutidine and 4-dimethylaminopyridine, and also bicyclic amines, such as DBU (1,8-Diaza- bicyclo(5.4.0)undec-7-ene) and DBN (1,5-Diazabicyclo[4.3.0]non-5-ene). Particular preference is given to alkali metal and alkaline earth metal hydroxides, such as LiOH, NaOH, KOH, and Ca(OH)2, such as NaOH, and KOH.
The bases are generally employed in catalytic amounts; however, they can also be used in equimolar amounts or in excess. Under certain conditions an excess up to 10 mol equivalents of base to compound II may be advantageous. For practical reasons hydroxylamine is preferably used in the form of an aqueous solution, alternatively as acid addition salt, such as halogenide or sulfate, preferably halogenide, particularly as HCI addition salt.
Hydroxylamine is generally employed in equimolar amounts; however, it can also be used in excess. Under certain conditions an excess up to 10 mol equivalents of hydroxylamine to compound II may be advantageous.
The catalyst III is used in 0.01 to 0.5, preferably 0.01 to 0.2, particularly about 0.02 to 0.1 mol equivalents of compound II. The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of hydroxyl amine, based on II.
Starting materials of formula II required for preparing the compounds I are commercially available or known from the literature or can be prepared as outlined above, or in accordance with the literature cited.
Compounds of formula III can preferably be prepared by alkylation of (R)-(6-methyl-4-quinolyl)- (5-vinylquinuclidin-2-yl)methanol (formula IV) with a compound of formula V wherein X is a leaving group, such as hydroxy or halogen, preferably Br or Cl; and Ra, Rb, p, and q have the meaning as given for formula III.
Figure imgf000006_0001
This transformation is usually carried out at temperatures of from 20°C to 110 °C, preferably from 25°C to 80°C, in an inert solvent [cf. WO 2011/104089]
Suitable solvents are aliphatic hydrocarbons such as pentane, hexane, cyclohexane, and petrol ether, aromatic hydrocarbons such as toluene, o-, m-, and p-xylene, halogenated hydrocarbons such as methylene chloride, chloroform, and chlorobenzene, ethers such as diethylether, diisopropylether, MTBE, dioxane, anisole, and tetrahydrofurane, nitrils such as acetonitrile, and propionitrile, moreover dimethyl sulphoxide, dimethyl formamide, and dimethylacetamide (DMA), preferably toluene, or acetonitrile. It is also possible to use mixtures of the solvents mentioned.
Formula IV and V compounds are known in the art and are commercially available.
The reaction mixtures are worked up in a customary manner, for example by mixing with water, separating the phases and, if appropriate, chromatographic purification of the crude products. Some of the intermediates and end products are obtained in the form of colourless or slightly brownish viscous oils which are purified or freed from volatile components under reduced pressure and at moderately elevated temperature. If the intermediates and end products are obtained as solids, purification can also be carried out by recrystallization or digestion.
However, if the synthesis yields mixtures of isomers, a separation is generally not necessarily required since in some cases the individual isomers can be interconverted during work-up for use or during application (for example under the action of light, acids or bases). Such conversions may also take place after use, e.g. in the treatment of plants in the treated plant.
The organic moieties mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The prefix Cn- Cm indicates in each case the possible number of carbon atoms in the group.
The term “halogen” denotes in each case fluorine, bromine, chlorine, or iodine, in particular fluorine, chlorine, or bromine.
The term "alkyl" as used herein and in the alkyl moieties of alkylamino, alkylcarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl and alkoxyalkyl denotes in each case a straight-chain or branched al kyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, prefer ably 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms. Examples of an alkyl group are methyl (“Me”), ethyl (“Et”), n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl (“ lBu”), n-pentyl, 1 -methyl butyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4- methylpentyl, 1 ,1-dimethylbutyl, 1 ,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1 ,2-trimethylpropyl, 1,2,2-trimethyl- propyl, 1-ethyl-1-methylpropyl, and 1-ethyl-2-methylpropyl.
The term "haloalkyl" as used herein and in the haloalkyl moieties of haloalkylcarbonyl, haloalk- oxycarbonyl, haloalkylthio, haloalkylsulfonyl, haloalkylsulfinyl, haloalkoxy and haloalkoxyalkyl, denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 car bon atoms, frequently from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms. Preferred haloalkyl moieties are selected from CrC4-haloalkyl, more preferably from CrC3-haloalkyl or CrC2-haloalkyl, in particular from Ci-C2-fluoroalkyl such as fluoromethyl, difluoromethyl, triflu- oromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2, 2-trif I u oroethy I , pentafluoroethyl, and the like.
The term "alkoxy" as used herein denotes in each case a straight-chain or branched alkyl group which is bonded via an oxygen atom and has usually from 1 to 10 carbon atoms, fre quently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Examples of an alkoxy group are methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyloxy, 2-butyloxy, iso-butyloxy, tert.-butyloxy, and the like.
The term "alkoxyalkyl" as used herein refers to alkyl usually comprising 1 to 10, frequently 1 to 4, preferably 1 to 2 carbon atoms, wherein 1 carbon atom carries an alkoxy radical usually comprising 1 to 4, preferably 1 or 2 carbon atoms as defined above. Examples are CH2OCH3, CH2-OC2H5, 2-(methoxy)ethyl, and 2-(ethoxy)ethyl.
The term "haloalkoxy" as used herein denotes in each case a straight-chain or branched alk oxy group having from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular fluorine atoms. Preferred haloalkoxy moieties include C1-C4- haloalkoxy, in particular CrC2-fluoroalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoro- methoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2- fluoroethoxy, 2-chloro-2,2-difluoro-ethoxy, 2,2dichloro-2-fluorethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and the like.
The term "alkylthio "(alkylsulfanyl: S-alkyl)" as used herein refers to a straight-chain or branched saturated alkyl group having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= CrC4-alkylthio), more preferably 1 to 3 carbon atoms, which is attached via a sulfur atom. The term "alkylsulfinyl" (alkylsulfoxyl: S(=0)-CrC6-alkyl), as used herein refers to a straight- chain or branched saturated alkyl group (as mentioned above) having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= CrC4-alkylsulfinyl), more preferably 1 to 3 carbon atoms bonded through the sulfur atom of the sulfinyl group at any position in the alkyl group.
The term "alkylsulfonyl" (S(=0)2-alkyl) as used herein refers to a straight-chain or branched saturated alkyl group having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C1-C4- alkylsulfonyl), preferably 1 to 3 carbon atoms, which is bonded via the sulfur atom of the sulfonyl group at any position in the alkyl group.
The term "alkylcarbonyl" refers to an alkyl group as defined above, which is bonded via the carbon atom of a carbonyl group (C=0) to the remainder of the molecule.
The term "alkoxycarbonyl" refers to an alkylcarbonyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
The term "alkenyl" as used herein denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl (2-methylprop-2-en-1-yl), 2-buten-1-yl, 3- buten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl, 2-ethylprop-2-en- 1-yl and the like.
The term "haloalkenyl" as used herein refers to an alkenyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.
The term "alkynyl" as used herein denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. ethynyl, propargyl (2-propyn-1-yl), 1-propyn-1-yl, 1-methylprop-2-yn-1-yl), 2-butyn-1-yl, 3-butyn-1-yl, 1- pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl, 1-methylbut-2-yn-1-yl, 1-ethylprop-2-yn-1-yl and the like.
The term "cycloalkyl" as used herein and in the cycloalkyl moieties of cycloalkoxy and cyclo- alkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl , cyclooctyl, cyclononyl, and cyclodecyl, or cyclopropyl (C-C3H5), cyclobutyl (C-C4H7), cyclopentyl (C-C5H9), and cyclohexyl (c-CeHn).
The term "halocycloalkyl" as used herein and in the halocycloalkyl moieties of halocycloalkoxy and halocycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 C atoms or 3 to 6 C atoms, wherein at least one, e.g. 1, 2, 3, 4 or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine. Examples are 1- and 2-flu- orocyclopropyl, 1,2-, 2,2- and 2,3-difluorocyclopropyl, 1,2,2-trifluorocyclopropyl, 2, 2,3,3- tetrafluorocyclpropyl, 1- and 2-chlorocyclopropyl, 1,2-, 2,2- and 2,3-dichlorocyclopropyl, 1,2,2- trichlorocyclopropyl, 2,2,3,3-tetrachlorocyclpropyl, 1-,2- and 3-fluorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-difluorocyclopentyl, 1-,2- and 3-chlorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5- dichlorocyclopentyl, and the like.
The term "cycloalkenyl" as used herein and in the cycloalkenyl moieties of cycloalkenyloxy and cycloalkenylthio denotes in each case a monocyclic singly unsaturated non-aromatic radical ha ving usually from 3 to 10, e.g. 3 or 4 or from 5 to 10 carbon atoms, preferably from 3- to 8 carbon atoms. Exemplary cycloalkenyl groups include cyclopropenyl, cycloheptenyl or cyclo- octenyl.
The term "cycloalkenylalkyl" refers to a cycloalkenyl group as defined above which is bonded via an alkylene group, such as a CrCs-alkyl group or a CrC4-alkyl group, in particular a methylene group (= cycloalkenylmethyl), to the remainder of the molecule.
The term “carbocycle” or “carbocyclyl” includes in general a 3- to 12-membered, preferably a 3- to 8-membered or a 5- to 8-membered, more preferably a 5- or 6-membered mono-cyclic, non-aromatic ring comprising 3 to 12, preferably 3 to 8 or 5 to 8, more preferably 5 or 6 carbon atoms. Preferably, the term “carbocycle” covers cycloalkyl and cycloalkenyl groups as defined above.
The term “heterocycle” or "heterocyclyl" includes in general 3- to 12-membered, preferably 5- or 6-membered, in particular 6-membered monocyclic heterocyclic non-aromatic radicals. The heterocyclic non-aromatic radicals usually comprise 1, 2 or 3 heteroatoms selected from N, O and S as ring members, wherein S-atoms as ring members may be present as S, SO or SO2. Examples of 5- or 6-membered heterocyclic radicals comprise saturated or unsaturated, non aromatic heterocyclic rings, such as 2- and 3-azetidinyl, 2- and 3-oxetanyl, 2- and 3-thietanyl, 2- and 3-thietanyl-S-oxid (S-oxothietanyl), 2- and 3-thietanyl-S-dioxid (S-dioxothietanyl), 2- and 3- pyrrolidinyl, 2- and 3-tetrahydrofuranyl, 1,3-dioxolan-2-yl, thiolan-2-yl, S-oxothiolan-2-yl, S-di- oxothiolan-2-yl, 4- and 5-oxazolidinyl, 1,3-dioxan-2-yl, 1- and 3-thiopyran-2-yl, S-oxothiopyranyl, and S-dioxothiopyranyl.
The term "hetaryl" includes monocyclic 5- or 6-membered heteroaromatic radicals comprising as ring members 1 , 2, or 3 heteroatoms selected from N, O and S. Examples of 5- or 6-mem- bered heteroaromatic radicals include pyridyl, i.e. 2-, 3-, and 4-pyridyl, pyrimidinyl, i.e. 2-, 4- and 5-pyrimidinyl, pyrazinyl, pyridazinyl, i.e. 3- and 4-pyridazinyl, thienyl, i.e. 2- and 3-thienyl, furyl, i.e. 2- and 3-furyl, pyrrolyl, i.e. 1-, 2- and 3-pyrrolyl, oxazolyl, i.e. 2-, 4- and 5-oxazolyl, isoxa- zolyl, i.e. 3-, 4- and 5-isoxazolyl, thiazolyl, i.e. 2-, 3- and 5-thiazolyl, isothiazolyl, i.e. 3-, 4- and 5-isothiazolyl, pyrazolyl, i.e. 1-, 3-, 4- and 5-pyrazolyl, imidazolyl, i.e. 1-, 2-, 4- and 5-imidazolyl, oxadiazolyl, e.g. 2- and 5-[1,3,4]oxadiazolyl, thiadiazolyl, e.g. 1,3,4-thiadiazol-5-yl, 1 ,2,4- thiadiazol-3-yl, triazolyl, e.g. 1 ,3,4-triazol-2-yl, and 1,2,4-triazol-3-yl.
The terms "heterocyclyolalkyl" and "hetarylalkyl" refer to heterocyclyl or hetaryl, resp., as defined above which are bound via a CrC4-alkyl group, in particular a methyl group (= hetero- cyclylmethyl or hetarylmethyl, resp.), to the remainder of the molecule.
With respect to the variables, the particularly preferred embodiments of the intermediates correspond to those of the compounds of the formula I.
In a particular embodiment, the variables of the compounds of the formula I have the following meanings, these meanings, both on their own and in combination with one another, being particular embodiments of the compounds of formula I.
In the compounds of the inventive process R1 is preferably fluoromethyl, in particular CF3.
The phenyl ring in formula I and its sub formulae, bearing the R2 n substitution is preferably a group P
R2a is preferably selected from
Figure imgf000009_0001
R2b and R2c are independently preferably selected from H, F, Cl, Br, CF3, and OCF3.
Particularly preferred is each one of the following combinations of R2a, R2b, and R2c wherein each line of Table A denotes a substitution pattern of the phenyl ring P bearing the R2a, R2b, and R2c moieties. Table A
Figure imgf000010_0002
Figure imgf000010_0001
Groups A-8, A-9, and A-11 are more preferred patterns in formula I and its sub formulae compounds. A-11 is particularly preferred.
R3 is preferably H, halogen, or CH3.
In a preferred embodiment G1 and G2 represent each CR3, wherein R3 is H, halogen, or C1-C4- alkyl, particularly G1 is CH and G2 is C-CI, or C-CH3.
In another preferred embodiment G1 and G2 represent each CR3, wherein the two R3 form a five- or sixmembered saturated carbocyclic ring, or a dihydrofurane.
The catalyst III is used preferably in an amount of 0.1-50 mol%, more preferred in 0.5-25 mol%, particularly in 1-10 mol% relative to formula II compounds.
The nature of the counteranion X- in formula III catalyst is of minor importance. For practical reasons it is usually selected from halogen (preferably Cl, Br), BF4, PF6, CrCio-alkylsulfonate, benzenesulfonate, or methylbenzenesulfonate. Preferred III is used as bromide and chloride, mesylate, and tosylate. Particularly preferred are bromide and chloride.
Ra is preferably CN, Ci-C3-alkyl, or Ci-C3-alkoxy, particularly CH3, or OCH3.
Rb is preferably Cl.
Index p is preferably 1 or 2, q is preferably 0 or 1.
Substituents Ra and Rb are preferably positioned in 2 and 6 position.
Particularly preferred are catalysts of formula III wherein the substitution of the pyridine group have the meanings as shown in Table II 1.1 , wherein each compound corresponds to one line. Table 111.1 ;
Figure imgf000011_0002
Figure imgf000011_0001
The bromides and chlorides of ill-1, 111-12, 111-21 , ill-26, and ill-27 are preferred embodiments.
Another embodiment relates to the process for obtaining compounds I wherein R5 is H or CH3, and R6 is H, CrC6-alkyl, C2-C6-alkenyl, which groups are unsubstituted or substituted with one or more same or different R8, wherein R8 is as defined and preferred above.
Another embodiment relates to the process for obtaining compounds I wherein R5 is H or CH3, and R6 is H, CrC6-alkyl, CrC4-alkoxy, or C2-C6-alkenyl, which groups are unsubstituted or substituted with one or more same or different R8, wherein R8 is as defined and preferred above.
The process is particularly suitable for synthesis of following active compounds of formula I, which correspond to formulae I. A, and I.B, resp., wherein the variables are as defined and preferred above: wherein Q is CH or O; and the other variables are as defined and preferred for formula I, and
Figure imgf000012_0001
wherein R3 is preferably H, CH3, or Cl, more preferably CH3 or Cl.
In formulae I.A and I.B group R5 is preferably H or CH3, and R6 is preferably H, CrC6-alkyl, Cr C2-alkoxy-CrC2-alkyl, or C2-C6-alkenyl.
In another embodiment of formulae I.A and I.B group R5 is preferably H or CH3, and R6 is preferably H, CrC6-alkyl, or CrC4-alkoxy.
Preferably the process yields in formula I compounds which obtained from the raw reaction mixture have an ee of at least 60%, more preferably 70%, even more preferably 80%, particularly at least 90% ee. Further enrichment of the S-enantiomer can be achieved by following recrystallisation.
The following examples illustrate the invention.
Examples
A. Preparation examples
With appropriate modification of the starting materials, the procedures given in the synthesis description were used to obtain further compounds I and III. The compounds obtained in this manner are listed in the tables that follow, together with physical data.
The products shown below were characterized by melting point determination, by NMR spectroscopy or by the masses ([m/z]) or retention time (RT; [min.]) determined by HPLC-MS or HPLC spectrometry.
HPLC-MS = high performance liquid chromatography-coupled mass spectrometry;
HPLC Method A: Agilent Series 1100, Column: Chiralpak AD-RH, 150mm * 4.6 mm ID * 5pm; Mobile Phase: A: water + 0,1vol% H3P04; B: acetonitrile + 0,1vol% H3P04; Temperature:
40°C; Gradient: 40% B to 70% B in 25 min; 70% B to 100% B in 5 min; 100% B 10min; 40% B 30.1 min; Flow: 1,2 mL/min; UV-detector BW= 5 nm, lambda = 240 nm.
HPLC Method B - Phenomenex Kinetex 1,7pm XB-C18 100A; 50 x 2,1 mm. Elution: acetonitrile + 0.1% trifluoroacetic acid (TFA) / water + 0.1% trifluoroacetic acid (TFA) in a ratio of from 5:95 to 95:5 in 1.5 minutes at 50°C.
Example 1: (R)-[(2S,4S,5R)-1-[(2-chloro-6-methoxy-4-pyridyl)methyl]-5-vinyl-quinuclidin-1-ium- 2-yl]-(6-methoxy-4-quinolyl)methanol chloride [111.2-2] To a solution of quinine [(R)-(6-methoxy-4-quinolyl)-[(2S,4S,5R)-5-vinylquinuclidin-2-yl]metha- nol, 844 mg, 2.60 mmol] in acetonitrile (10 ml_) was added 4-chloromethyl-2-chloro-6-methoxy pyridine (500 mg, 2.60 mmol) and the mixture was stirred at reflux overnight. After completion of the reaction, the mixture was diluted with MTBE (100 ml_) and the resulting precipitate was collected via filtration. After drying in vacuum, the title compound was obtained (780 mg, 52%) as colorless solid.
Method B HPLC-MS: RT = 0.897 min, m/z = 480.1 [MH-CI]
1H-NMR (400 MHz, CDCh): 1.47 (m, 1H), 1.74 (m, 1 H), 2.01 (s, 1 H), 2.12 (m, 1 H), 2.23 (m, 1H), 2.56 (m, 1H), 3.05 (m, 1H), 3.30 (m, 1H), 3.88 (s, 3H), 3.94 (s, 3H), 4.13 (m, 1H), 4.20 (m, 1H), 4.88 (m, 1H), 4.94 (d, 1 H), 5.21 (d, 1H), 5.48-5.61 (m, 2H), 5.87 (d, 1H), 6.47 (s, 1 H), 7.19 (m, 1 H), 7.21 (s, 1H), 7.36 (s, 1H), 7.39 (s, 1 H), 7.74 (m, 1H), 7.89 (d, 1 H), 8.60 (m, 1 H).
Example 2: (R)-(6-methoxy-4-quinolyl)-[(2S,4S,5R)-1-[(2-methyl-4-pyridyl)methyl]-5-vinyl- quinuclidin-1-ium-2-yl]methanol chloride [III.2-3]
To a solution of quinine [(R)-(6-methoxy-4-quinolyl)-[(2S,4S,5R)-5-vinylquinuclidin-2-yl]metha- nol, 910 mg, 2.81 mmol, 1.00 equiv.) in acetonitrile (10 ml_) was added 4-chloromethyl-2-methyl pyridine (500 mg, 2.81 mmol) and the mixture was stirred at reflux overnight. After completion of the reaction, the mixture was diluted with MTBE (100 ml_) and the resulting precipitate was collected via filtration. After drying in vacuum, the title compound was obtained (729 mg, 53%) as colourless solid.
Method B HPLC-MS: RT = 0.666 min, m/z = 430.1 [MH-CI]
1H-NMR (400 MHz, CDCI3): 1.46 (m, 1 H), 1.73 (m, 1 H), 2.01 (s, 1 H), 2.08-2.29 (m, 3H), 2.52 (s, 1 H), 2.54 (m, 1 H), 3.04 (m, 1H), 3.29 (m, 1 H), 3.61 (m, 1 H), 3.94 (s, 3H), 3.96 (m, 1 H), 4.89- 5.04 (m, 2H), 5.13 (m, 1H), 5.19 (s, 1 H), 5.56 (m, 1H), 6.00 (d, 1 H), 6.51 (s, 1H), 7.25 (m, 1 H), 7.41 (m, 1 H), 7.51 (m, 2H), 7.73 (m, 1H), 7.89 (d, 1 H), 8.8.46 (m, 1H), 8.64 (m, 1H).
Example 3: (R)-[(2S,4S,5R)-1-[(2,6-dimethyl-4-pyridyl)methyl]-5-vinyl-quinuclidin-1-ium-2-yl]- (6-methoxy-4-quinolyl)methanol bromide [111.2-4]
Step 1: Preparation of (2,6-dimethyl-4-pyridyl)methanol
Sulphuric acid (7.8 mL) and methanol (204 mL) were mixed under ice cooling. This mixture was added to a solution of ammonium persulfate (65.87 g, 289.0 mmol, 1.97 equiv.) in water (102 mL), before 2,6-lutidine (17.1 mL, 15.7 g, 147 mmol, 1.00 equiv.) was added dropwise.
The resulting suspension was heated at 100°C for 24 h and became an orange solution. After cooling, the mixture was concentrated in vacuum to remove the methanol and made alkaline using aqueous NaOH (200 mL of a 1 M solution) under ice cooling. Extraction with dichloro- methane (3 x 150 mL), drying the combined organic phases over Na2SC>4 and concentration in vacuum yielded the crude product (7.7 g) which was purified via flash chromatography on silica gel using cyclohexane with 1% triethylamine and ethyl acetate to yield the title compound (2.3 g, 11%).
1H-NMR (400 MHz, CDCh): 2.51 (s, 6H), 4.67 (s, 2H), 6.96 (s, 2H).
Step 2: Preparation of 4-(bromomethyl)-2, 6-dimethyl-pyridine
(2,6-dimethyl-4-pyridyl)methanol (0.50 g, 3.6 mmol) in HBr (4.0 mL of a 33% solution in glacial acetic acid, 22 mmol, 6.0 equiv.) were heated at reflux for 5 h. After cooling, the mixture was concentrated in vacuum, poured onto ice-water and made alkaline with NaOH (20% in water). The resulting mixture was extracted with ethyl acetate and combined organic layers were washed with water, brine, and dried over Na2SC>4. After concentration in vacuum, the title compound (0.62 g, 85%) was obtained.
1H-NMR (400 MHz, CDCI3): 2.53 (s, 6H), 4.33 (s, 2H), 6.97 (s, 2H).
Step 3: Preparation of (R)-[(2S,4S,5R)-1-[(2,6-dimethyl-4-pyridyl)methyl]-5-vinyl-quinuclidin-1- ium-2-yl]-(6-methoxy-4-quinolyl)methanol bromide [111.2-4]
To a solution of quinine ((R)-(6-methoxy-4-quinolyl)-[(2S,4S,5R)-5-vinylquinuclidin-2-yl]metha- nol, 445 mg, 1.37 mmol) in acetonitrile (10 ml_) was added 4-(bromomethyl)-2, 6-dimethyl- pyridine (274 mg, 1.37 mmol, 1.00 equiv.) and the mixture was stirred at reflux overnight. After completion of the reaction, the mixture was diluted with MTBE (100 ml_) and the resulting precipitate was collected via filtration. After drying in vacuum, the title compound was obtained (472 mg, 66%) as colourless solid.
1H-NMR (400 MHz, CDCh): 1.52 (m, 1 H), 1.73-1.82 (m, 2H), 2.03 (s, 1H), 2.29 (m, 2H), 2.51 (s, 6H), 2.63 (m, 1 H), 3.20 (m, 1H), 3.32 (m, 1H), 3.50 (m, 1 H), 3.88 (m, 1 H), 3.95 (s, 3H), 4.88 (d, 1H), 5.02 (m, 1H), 5.09 (d, 1H), 5.13 (d, 1H), 5.60 (m, 1 H)6.06 (d, 1 H), 6.50 (d, 1H), 6.63 (m, 1H), 7.24-7.32 (m, 4H), 7.71 (d, 1H), 8.00 (d, 1 H), 8.71 (m, 1 H).
Example 4: N-[[4-[(5S)-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2, 3-dihydro- benzofuran-7-yl]methyl]propanamide [I.A-1]
A mixture of N-[[4-[(E/Z)-3-(3,5-dichlorophenyl)-4,4,4-trifluoro-but-2-enoyl]-2,3-dihydrobenzo- furan-7-yl]methyl]propenamide (1.00 g, 2.12 g; known from PCT/EP2019/079324) in dichloro- methane (10 ml_) was suspended at 0°C and (R)-[(2S,4S,5R)-1-[(2-chloro-6-methoxy-4-pyri- dyl)methyl]-5-vinyl-quinuclidin-1-ium-2-yl]-(6-methoxy-4-quinolyl)methanol chloride (55 mg, 0.11 mmol, 5 mol-%) was added. The temperature was lowered to -10°C and a pre-cooled mixture of aqueous NaOH (1.69 g of a 20% solution in water, 8.47 mmol, 4 equiv.) and hydroxylamine (0.42 g of a 50% solution in water, 6.35 mmol, 3 equiv.) was added slowly. After 6 h at -10°C, aqueous hydrochloric acid (10 mL of a 1 M solution) was added and allowed to reach room temperature. All volatile solvents were removed in vacuum, then water (20 mL) was added and sonicated. The resulting precipitate was collected by filtration and washed with water (3 x 30 mL) and pentane (3 x 15 mL) to obtain the crude product (880 mg). After recrystallization from methanol the title compound (440 mg, 41%; enantiomeric ratio > 99:1) was obtained as colorless solid.
Method A HPLC: RT = 18.615 min (S-isomer); 22.085 min (R-isomer)
1H-NMR (400 MHz, DMSO-d6): 1.02 (t, 3H), 2.16 (q, 2H), 3.38 (m, 2H), 4.20 (m, 2H), 4.28 (d, 1H), 4.35 (d, 1H), 4.60 (m, 2H), 7.05-7.11 (m, 2H), 7.64 (s, 2H), 7.80 (s, 1H), 8.20 (m, 1H).
Example 5: tert-butyl N-[[7-[(5S)-5-(3,5-dichloro-4-fluoro-phenyl)-5-(trifluoromethyl)-4H- isoxazol-3-yl]indan-4-yl]methyl]carbamate [I . A-2]
Step 1 : Preparation of (7-acetylindan-4-yl) trifluoromethanesulfonate
To a suspension of 1-(7-hydroxyindan-4-yl)ethanone (known from W02016/141890, 5.00 g, 28.4 mmol) in dichloromethane (50 mL) was added triethylamine (7.9 mL, 5.8 g, 2.0 equiv.) at 0- 5°C. After completed addition, triflic anhydride (5.7 mL, 9.6 g, 1.2 equiv.) was added and the mixture was allowed to reach 20-25°C. After 30 min, the reaction was complete and poured onto ice-water. The dichloromethane phase was separated, and the aqueous layer was extracted with dichloromethane (3 x 50 mL). Combined organic layers were washed with saturated aqueous NaHC03 solution (2 x 70 ml_), water (70 ml_) and dried over Na2SC>4. After concentration in vacuum the title compound (8.7 g, 99%) was obtained.
Method B HPLC-MS: RT = 1.278 min, m/z = 308.7 [M+H]
1H-NMR (400 MHz, CDCh): 2.19 (m, 2H), 2.61 (s, 3H), 3.02 (m, 2H), 3.35 (m, 2H), 7.16 (d,
1H), 7.75 (d, 1H).
Step 2: Preparation of 7-acetylindane-4-carbonitrile
To a solution of (7-acetylindan-4-yl) trifluoromethanesulfonate (34.50 g, 111.9 mmol) in DMA (250 ml_) was added Zn(CN)2 (19.71 g, 167.9 mmol, 1.50 equiv.) and the mixture was degassed with argon, before tetrakis(triphenylphosphine) palladium (25.87 g, 22.38 mmol, 20.0 mol-%) was added. The mixture was stirred at 140°C for 16 h, cooled and stirred into ice-water (750 ml_). Ethyl acetate (300 ml_) was added and all solids were removed by filtration over celite. The layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 100 ml_). Combined organic layers were washed with water (3 x 500 ml_) and dried over Na2SC>4. After concentration in vacuum, the residue was purified via flash chromatography on silica gel to yield the title compound (18.00 g, 87%).
1H-NMR (400 MHz, CDCh): 2.19 (m, 2H), 2.61 (s, 3H), 3.13 (m, 2H), 3.31 (m, 2H), 7.55 (d,
1H), 7.72 (d, 1H).
Step 3: Preparation of tert-butyl N-[(7-acetylindan-4-yl)methyl]carbamate
A mixture of benzyl 7-acetylindane-4-carbonitrile (3.30 g, 17.8 mmol), Boc-anhydride (11.67 g, 53 mmol, 3 equiv.) and Raney-nickel in methanol (50 ml_) was stirred under an atmosphere of hydrogen at room temperature overnight. After completion of the reaction, the mixture was filtered over a plug of celite and washed with methanol (3 x 30 ml_). The filtrate was concen trated in vacuum and the resulting residue was triturated in n-pentane (15 ml_) to obtain the title compound (2.70 g, 52%).
1H-NMR (400 MHz, CDCh): 1.48 (s, 9H), 2.09 (m, 2H), 2.58 (s, 3H), 2.86 (m, 2H), 3.27 (m,
2H), 4.32 (m, 2H), 4.81 (br. s, 1H), 7.19 (d, 1 H), 7.68 (d, 1H).
Step 4: Preparation of tert-butyl N-[[7-[(E/Z)-3-(3,5-dichloro-4-fluoro-phenyl)-4,4,4-trifluoro-but- 2-enoyl]indan-4-yl]methyl]carbamate
A mixture of tert-butyl N-[(7-acetylindan-4-yl)methyl]carbamate (12.00 g, 41.47 mmol), K2CCh (8.60 g, 62.2 mmol, 1.50 equiv.), CsCI (698 mg, 4.15 mmol, 10.0 mol-%) and 1-(3,5-dichloro-4- fluoro-phenyl)-2,2,2-trifluoro-ethanone (16.24 g, 62.20 mmol, 1.50 equiv.) and toluene (200 ml_) were heated at reflux in a Dean-Stark trap for 16 h. After cooling, the solvent was removed in vacuum. Water (120 ml_) was added to the residue and the resulting precipitate was collected by filtration as pure E-isomer title compound (12.5 g, 57%).
Method B HPLC-MS: RT = 1.515 min, m/z = 475.8 [M-lbu]
1H-NMR (500 MHz, CDCh): 1.49 (s, 9H), 2.09 (m, 2H), 2.85 (m, 2H), 3.12 (m, 2H), 4.31 (m, 2H), 4.82 (br. s, 1H), 7.19 (d, 1 H), 7.20 (d, 2H), 7.35 (s, 1 H), 7.48 (d, 1H).
Step 5: Preparation of tert-butyl N-[[7-[(5S)-5-(3,5-dichloro-4-fluoro-phenyl)-5-(trifluoromethyl)- 4H-isoxazol-3-yl]indan-4-yl]methyl]carbamate
A mixture of tert-butyl N-[[7-[(E/Z)-3-(3,5-dichloro-4-fluoro-phenyl)-4,4,4-trifluoro-but-2-en- oyl]indan-4-yl]methyl]carbamate12.50 g, 23.48 mmol) and dichloromethane (120 mL) was cooled to 0°C and (R)-[(2S,4S,5R)-1-[(2,6-dimethyl-4-pyridyl)methyl]-5-vinyl-quinuclidin-1-ium-2- yl]-(6-methoxy-4-quinolyl)methanol bromide (616 mg, 1.17 mmol, 5.00 mol-%) was added and the mixture was cooled to -10°C. A pre-cooled mixture of aqueous hydroxylamine (4.54 g of a 50% solution in water, 70.4 mmol, 3 equiv.) and aqueous NaOH (18.8 g of a 20% solution in water, 93.9 mmol, 4 equiv.) was added drop wise. After stirring overnight at -10°C, aqueous hydrochloric acid (120 ml_) was added and allowed to reach 20-25°C. The organic solvent was removed in vacuum and the aqueous phase was extracted with ethyl acetate (3 x 80 ml_). Combined organic layers were dried over Na2SC>4 and concentrated in vacuum. The residue was purified via flash chromatography on silica-gel to yield the title compound (12.90 g, 95% purity, 95 % yield; enantiomeric ratio = 82:18).
Method B HPLC-MS: RT = 1.590 min, m/z = 491.0 [M-lbu]
Method A HPLC RT = 20.503 min (R-isomer); 22.260 min (S-isomer)
1H-NMR (400 MHz, CDCh): 1.45 (s, 9H), 2.14 (m, 2H), 2.92 (m, 2H), 3.18 (m, 2H), 3.73 (d, 1 H), 4.11 (d, 1 H), 4.32 (m, 2H), 4.80 (br. s, 1 H), 7.16 (s, 2H), 7.59 (d, 2H).
Example 6: N-[[4-[(5S)-5-(3,5-dichloro-4-fluoro-phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]- 2,3-dihydrobenzofuran-7-yl]methyl]propanamide [I.A-3]
A mixture of N-[[4-[(E/Z)-3-(3,5-dichloro-4-fluorophenyl)-4,4,4-trifluoro-but-2-enoyl]-2,3-di- hydrobenzofuran-7-yl]methyl]propenamide (1.00 g, 2.12 g) in dichloromethane (10 ml_) was suspended at 0°C and (R)-[(2S,4S,5R)-1-[(2,6-dimethyl-4-pyridyl)methyl]-5-vinyl-quinuclidin-1- ium-2-yl]-(6-methoxy-4-quinolyl)methanol bromide (53 mg, 0.10 mmol, 5 mol-%) was added. The temperature was lowered to -10°C and a pre-cooled mixture of aq. NaOH (1.63 g of a 20% solution in water, 8.16 mmol, 4 equiv.) and hydroxylamine (0.40 g of a 50% solution in water,
6.1 mmol, 3 equiv.) was added slowly. After 6 h at -10°C, aq. HCI (10 mL of a 1 M solution) was added and allowed to reach 20-25°C. All volatile solvents were removed in vacuum, then water (20 mL) was added and sonicated. The resulting precipitate was collected by filtration and washed with water (3 x 30 mL) and pentane (3 x 15 mL) to obtain the crude product (960 mg). Recrystallization from methanol yielded the title compound (651 mg, 70%; enantiomeric ratio = 98:2).
Method A HPLC: RT = 18.391 min (S-isomer), 19.982 min (R-isomer)
1H-NMR (400 MHz, CDCh): 1.16 (t, 3H), 2.22 (q, 2H), 3.48 (m, 2H), 3.61 (d, 1 H), 4.10 (d, 1 H), 6.00 (br. s, 1 H), 6.79 (d, 1 H), 7.15 (d, 1 H), 7.58 (d, 2H).
Catalysts III
Figure imgf000016_0001
Table 111.2
Figure imgf000016_0002
Figure imgf000017_0002
Preparation of formula I compounds
Figure imgf000017_0001
Figure imgf000017_0003
Figure imgf000017_0004
Examples according to the invention
Figure imgf000017_0005
Comparisons with catalysts III* known from WO 2011/104089 (# being the bond to the remainder of formula III*):
Figure imgf000017_0006
Figure imgf000018_0001
Comparisons with other catalysts III* not according to the invention
Figure imgf000018_0002

Claims

Claims:
1 A process for preparing optically enriched isoxazoline compounds of formula I
Figure imgf000019_0001
wherein
R1 is halomethyl; each R2 is independently H, halogen, CN, I , NO2, SCN, SF5, CrC6-alkyl, C3-C8- cycloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, which groups are unsubstituted, partially or fully halogenated and/or substituted with one or more same or different R8;
OR9, or S(0)nR9, n is 0, 1, or 2;
G1, G2 are each CR3; each R3 is independently selected from the meanings mentioned for R2or is C(=0)R8, or two R3 bonded to adjacent carbon atoms may form a five- or sixmembered saturated, partially or fully unsaturated carbocyclic ring, or a dihydrofurane;
W is O or S;
R5 is independently selected from the meanings mentioned for R2;
R6 is H, Ci-Cio-alkyl, Cs-Cs-cycloalkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, which groups are unsubstituted, partially or fully halogenated and/or substituted with one or more same or different R8; or CrC4-alkoxy, S(0)nR9, or C(=0)R8; or a 3- to 8-membered saturated, partially or fully unsaturated heterocyclic ring, which ring may contain 1, 2, 3, or 4 heteroatoms O, S, N, C=0 and/or C=S as ring members, which heterocyclic ring is unsubstituted or partially or fully substituted with same or different halogen, CN, CrC6-alkyl, Ci-C6-haloalkyl, CrC6-alkoxy, C1-C6- haloalkoxy, CrC6-alkylthio, CrC6-haloalkylthio, Cs-Cs-cycloalkyl, C3-C8- halocycloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C2-C6-haloalkynyl, which groups are unsubstituted, or partially or fully substituted with same or different R8, or phenyl which may be partially or fully substituted with R11; each R8 is independently CN, N3, NO2, SCN, SF5, Cs-Cs-cycloalkyl, Cs-Cs-halocyclo- alkyl;
Si(R12)s, OR9, OSO2R9, S(0)nR9, N(R10a)R10b, C(=O)N(R10a)R10b, C(=S)N(R10a)R10b, C(=0)OR9, CH=NOR9, phenyl, or a 3-, 4-, 5-, 6- or 7-membered saturated, partially or fully unsaturated heterocyclic ring comprising 1, 2 or 3 heteroatoms N, O, and/or S as ring members, or two R8 present on the same carbon atom of an alkyl, alkenyl, alkynyl or cycloalkyl group together form a group =0, =C(R13)2; =S; =S(0)m(R15)2, =S(0)mR15N(R14a)R14b,
=NR10a, =NOR9; or =NN(R10a)R10b; or two radicals R8, together with the carbon atoms of the alkyl, alkenyl, alkynyl or cycloalkyl group which they are bonded to, form a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or partially unsaturated carbocyclic or heterocyclic ring, which heterocyclic ring comprises 1 , 2, 3 or 4 heteroatoms N, O, and/or S as ring members; and R8 as a substituent on a cycloalkyl ring may additionally be CrC6-alkyl, Ci-C6-haloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, and C2-C6-haloalkynyl; and R8 in the groups C(=0)R8 and =C(R8)2 may additionally be H, halogen, CrC6-alkyl, C C6- haloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, or C2-C6-haloalkynyl; each R9 is independently H, CrC6-alkyl, or CrC6-haloalkyl;
R10a, Riob are independently from one another H, CrC6-alkyl, CrC6-haloalkyl, C3-Cs- cycloalkyl, C3-C8-halocycloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C2- C6-haloalkynyl;
CrC6-alkyl-C(=0)0R15, C C6-alkyl-C(=0)N(R14a)R14b, C C6-alkyl-C(=S)N(R14a)R14b, Ci-C6-alkyl-C(=NR14)N(R14a)R14b, CrCe-alkoxy, CrCe-haloalkoxy, Ci-C6-alkylthio, CrCe-haloalkylthio, S(0)nR15, S(0)nN(R14a)R14b, C(=0)R13, C(=0)OR15, C(=0)N(R14a)R14b,
C(=S)R13, C(=S)SR15, C(=S)N(R14a)R14b, C(=NR14)R13; phenyl; and a 3-, 4-, 5-, 6- or 7-membered saturated, partially or fully unsaturated heterocyclic ring comprising 1 , 2, 3 or 4 heteroatoms N, O, and/or S as ring members, preferably hetaryl; or
R10a and R10b together with the nitrogen atom they are bonded to form a 3- to 8-membered saturated, partially or fully unsaturated heterocyclic ring, which ring may additionally contain one or two heteroatoms N, O, and/or S as ring members; or
R10a and R10b together form a group =C(R13)2, =S(0)m(R15)2, =S(0)mR15N(R14a)R14b, =NR14, or =NOR15;
R11 is halogen, CN, N3, NO2, SCN, SF5, Ci-Cio-alkyl, C3-C8-cycloalkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, or
OR9, NR10aR10b, S(0)nR9, Si(R12)3; phenyl; and a 3- to 7-membered saturated, partially or fully unsaturated aromatic heterocyclic ring comprising 1 , 2, 3, or 4 heteroatoms N, O, and/or S as ring members; or two R11 present on the same ring carbon atom of an unsaturated or partially unsaturated heterocyclic ring may together form a group =0, =C(R13)2, =S, =S(0)m(R15)2, =S(0)mR15N(R14a)R14b, =NR14, =NOR15, or =NN(R14a)R14b; or two R11 bound on adjacent ring atoms form together with the ring atoms to which they are bound a saturated 3- to 9-membered ring, which ring may contain 1 or 2 heteroatoms O, S, N, and/or NR14, and/or 1 or 2 groups C=0, C=S, C=NR14 as ring members; each R12 is independently CrC4-alkyl and phenyl; each R13 is independently CN, NO2, OH, SH, SCN, SF5, CrC6-alkoxy, CrC6-halo- alkoxy, SOn-Ci-C6-alkyl, SOn-Ci-C6-haloalkyl, Si(R12)3, C(=0)N(R14a)R14b,
OrCs-cycloalkyl; and a 3- to 7-membered saturated, partially or fully unsaturated heterocyclic ring containing 1 , 2, or 3 heteroatoms N, O, and/or S, as ring members; or two R13 present on the same carbon atom of an alkyl, alkenyl, alkynyl or cycloalkyl group may together be =0, =CH(Ci-C4-alkyl), =C(Ci-C4-alkyl)Ci-C4-alkyl, =N(Ci-C6-alkyl) or =NO(Ci-C6-alkyl); and
R13 as a substituent of a cycloalkyl ring may additionally be Ci-Ce-alkyl, C2-C6-alkenyl or C2-Ce-alkynyl, which groups are unsubstituted, partially or fully halogenated, or substituted with 1 or 2 CN, C3-C4-cycloalkyl, CrC4-alkoxy, Ci-C4-haloalkoxy, and oxo; and
R13 in groups =C(R13)2, N=C(R13)2, C(=0)R13, C(=S)R13, and C(=NR14)R13 may additionally be H, halogen, Ci-Ce-alkyl, C2-C6-alkenyl, or C2-C6-alkynyl, and oxo; each R14 is independently H, CN, CrC6-alkoxy, CrC6-haloalkoxy, SOn-CrC6-alkyl, SOn- CrC6-haloalkyl, Si(R12)3; CrC6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl; and oxo; Cs-Cs-cycloalkyl; phenyl, benzyl, pyridyl, phenoxy; and a 3-, 4-, 5- or 6-membered saturated, partially or fully unsaturated heterocyclic ring comprising 1, 2 or 3 heteroatoms N, O, and/or S as ring members;
R14a and R14b independently of each other, have one of the meanings given for R14; or R14a and R14b, together with the nitrogen atom to which they are bound, form a 3- to 7- membered saturated, partially, or fully unsaturated heterocyclic ring, wherein the ring may additionally contain 1 or 2 heteroatoms N, O, and/or S as ring members; or R14a and R14 or R14b and R14, together with the nitrogen atoms to which they are bound in the group C(=NR14)N(R14a)R14b, form a 3- to 7-membered partially, or fully unsaturated heterocyclic ring, wherein the ring may additionally contain 1 or 2 heteroatoms N, O, and/or S as ring members; each R15 is independently H, CN, Si(R12)3, CrC6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl; Cs- Cs-cycloalkyl; phenyl, benzyl, pyridyl, and phenoxy; each R16 is independently halogen, NO2, CN, OH, SH, CrC6-alkoxy, CrC6-haloalkoxy, SOn-Ci-C6-alkyl, SOn-CrC6-haloalkyl, CrC4-alkylcarbonyl, CrC4-haloalkylcarbonyl, Ci-C4-alkoxycarbonyl, Ci-C4-haloalkoxycarbonyl, aminocarbonyl, Ci-C4-alkylamino- carbonyl, di-(Ci-C4-alkyl)-aminocarbonyl, Si(R12)3; CrC6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl; Cs-Cs-cycloalkyl; or two R16 present together on the same atom of an unsaturated or partially unsaturated ring may be =0, =S, =N(Ci-Cs-alkyl), =NO-Ci-Cs-alkyl, =CH(CrC4-alkyl), or =C(Ci-C4- alkyl)2; or two R16 on two adjacent carbon atoms form together with the carbon atoms they are bonded to a 4- to 8-membered saturated, partially or fully unsaturated ring, wherein the ring may contain 1 or 2 heteroatoms N, O, and/or S as ring members; each n is independently 0, 1, or 2; and each m is independently 0, or 1 ; wherein the shown enantiomer has at least 55% ee; by oxo-Michael addition of hydroxyl amine or its salt to an enone of formula II,
Figure imgf000021_0001
wherein the variables have the meanings given for formula I, in the presence of a catalyst of formula III
Figure imgf000021_0002
wherein X is a counteranion, and
Ra is CN, CrC3-alkyl, CrC3-alkoxy, CrC3-alkylthio, phenyl, benzyl, and phenoxy; Rb is halogen; p is 1, 2, 3, or 4; and q is 0, 1 , 2 or 3, wherein the sum of p and q is up to 4; and a base.
2. A process according to claim 1, wherein the phenyl ring in formula I bearing the R2 n substitution is a group P wherein
Figure imgf000022_0002
e H, or as defined for R2a.
3. A process according to any of the preceding claims, wherein R1 is CF3.
4. A process according to any of the preceding claims, wherein G1 is C-CH3, or C-CI, and G2 is CH.
5. A process according to any of claims 1 to 3, wherein formula I corresponds to formula I. A,
Figure imgf000022_0001
wherein Q is CH or O, R5 is H or CH3, and R6 is H, CrC6-alkyl, Ci-C2-alkoxy-Ci-C2-alkyl, or C2-C6-alkenyl.
6. A process according to any of claims 1 to 4, wherein formula I is formula I.B,
Figure imgf000022_0003
wherein R5 is H or CH3, and R6 is H, CrC6-alkyl, Ci-C2-alkoxy-Ci-C2-alkyl, or C2-C6- alkenyl.
7. A process according to any of the preceding claims, wherein the catalyst of formula III is applied in 0.01 to 0.5 mol equivalents of compound II.
8. A process according to any of the preceding claims, wherein an alkali metal or alkaline earth metal hydroxide is used as base in from 0.05 to 6 mol equivalents.
9. A process according to any of the preceding claims, wherein the amount of hydroxylamine is from 1 to 10 mol equivalents.
10. A compound of formula III
Figure imgf000023_0001
wherein X is halogen, BF4, PF6, Ci-Cio-alkylsulfonate, benzenesulfonate, or methylbenzenesulfonate; is CN, CrC3-alkyl, CrC3-alkoxy, CrC3-alkylthio, phenyl, benzyl, and phenoxy; is halogen; p is 1, 2, 3, or 4; and q is 0, 1 , 2 or 3, wherein the sum of p and q is up to 4.
11. A compound of formula III according to claim 11, wherein
(Ra)p and (Rb)q are selected from 2-CN, 2-OCH3, and 3-CH3 .
12. A compound of formula III according to claim 11, wherein
(Ra)p and (Rb)q are selected from 2-CH3, 2-OCH3,6-CI, and 2-OCH3,6-CH3.
13. A compound of formula III according to claim 11, wherein (Ra)p is 2,6-(CH3)2, and q is 0.
14. A compound of formula III according to any of claims 11 to 13, wherein X is halogen.
15. A compound of formula III according to claim 14, wherein X is Br or Cl.
PCT/EP2021/057228 2020-03-31 2021-03-22 Process for preparation of optically enriched isoxazolines WO2021197880A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20167213.6 2020-03-31
EP20167213 2020-03-31

Publications (1)

Publication Number Publication Date
WO2021197880A1 true WO2021197880A1 (en) 2021-10-07

Family

ID=70110154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/057228 WO2021197880A1 (en) 2020-03-31 2021-03-22 Process for preparation of optically enriched isoxazolines

Country Status (1)

Country Link
WO (1) WO2021197880A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023031061A1 (en) 2021-08-30 2023-03-09 Syngenta Crop Protection Ag Process for the preparation of an optically active isoxazoline compound
WO2023152340A1 (en) 2022-02-10 2023-08-17 Syngenta Crop Protection Ag Insect, acarina and nematode pest control
WO2023203038A1 (en) 2022-04-19 2023-10-26 Syngenta Crop Protection Ag Insect, acarina and nematode pest control
WO2023232560A1 (en) 2022-05-30 2023-12-07 Syngenta Crop Protection Ag Process for the preparation of 4-substituted 2-oxazolidinones

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007105814A1 (en) 2006-03-10 2007-09-20 Nissan Chemical Industries, Ltd. Substituted isoxazoline compound and pest control agent
WO2009063910A1 (en) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. Method for catalytic asymmetric synthesis of optically active isoxazoline compound
WO2011104089A1 (en) 2010-02-25 2011-09-01 Syngenta Participations Ag Process for the preparation of isoxazoline derivatives
US20140350261A1 (en) * 2011-11-08 2014-11-27 Nissan Chemical Industries, Ltd. Method for catalytic asymmetric synthesis of optically active isoxazoline compound, and optically active isoxazoline compound
WO2016141890A1 (en) 2015-03-12 2016-09-15 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus inhibitors and pharmaceutical uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007105814A1 (en) 2006-03-10 2007-09-20 Nissan Chemical Industries, Ltd. Substituted isoxazoline compound and pest control agent
WO2009063910A1 (en) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. Method for catalytic asymmetric synthesis of optically active isoxazoline compound
WO2011104089A1 (en) 2010-02-25 2011-09-01 Syngenta Participations Ag Process for the preparation of isoxazoline derivatives
US20140350261A1 (en) * 2011-11-08 2014-11-27 Nissan Chemical Industries, Ltd. Method for catalytic asymmetric synthesis of optically active isoxazoline compound, and optically active isoxazoline compound
WO2016141890A1 (en) 2015-03-12 2016-09-15 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus inhibitors and pharmaceutical uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023031061A1 (en) 2021-08-30 2023-03-09 Syngenta Crop Protection Ag Process for the preparation of an optically active isoxazoline compound
WO2023152340A1 (en) 2022-02-10 2023-08-17 Syngenta Crop Protection Ag Insect, acarina and nematode pest control
WO2023203038A1 (en) 2022-04-19 2023-10-26 Syngenta Crop Protection Ag Insect, acarina and nematode pest control
WO2023232560A1 (en) 2022-05-30 2023-12-07 Syngenta Crop Protection Ag Process for the preparation of 4-substituted 2-oxazolidinones

Similar Documents

Publication Publication Date Title
WO2021197880A1 (en) Process for preparation of optically enriched isoxazolines
AU2016260784B2 (en) Process for preparing 4-amino-pyridazines
KR102542215B1 (en) 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones
AU2017216082B2 (en) Catalytic hydrogenation process for preparing pyrazoles
WO2020088949A1 (en) Process for preparation of optically enriched aldol compounds
WO2021228673A1 (en) Process for preparation of optically enriched isoxazolines
CN112969690A (en) Process for preparing optically enriched isoxazolines
CN107324982B (en) 1-trifluoromethyl-tetrasubstituted cyclopentene derivative and preparation method and application thereof
JP7161275B2 (en) Method for producing 4-amino-pyridazine
KR102087160B1 (en) Pyridine n-oxides and processes for their preparation
RU2778306C1 (en) Method for preparation of 4-aminopyridines
JPWO2017195894A1 (en) Method for producing 2-acetylpyridine compound
JP2013151452A (en) Imine derivative containing optically activity trifluoromethyl group, method of manufacturing the same, and method of manufacturing optical activity amine derivative containing trifluoromethyl group using the same
JP2019023164A (en) Process for producing biphenyl compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21712847

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21712847

Country of ref document: EP

Kind code of ref document: A1